{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:18:28Z","timestamp":1772497108422,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T00:00:00Z","timestamp":1549670400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00011-019-01218-y","type":"journal-article","created":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T08:42:03Z","timestamp":1549701723000},"page":"261-274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study"],"prefix":"10.1007","volume":"68","author":[{"given":"David L.","family":"Boyle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel E.","family":"DePrimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Calderon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dion","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Dunford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Barchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary S.","family":"Firestein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin L.","family":"Thurmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,9]]},"reference":[{"key":"1218_CR1","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1124\/pr.114.010249","volume":"67","author":"P Panula","year":"2015","unstructured":"Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WL, et al. International union of basic and clinical pharmacology. XCVIII. Histamine receptors. Pharmacol Rev. 2015;67:601\u201355.","journal-title":"Pharmacol Rev"},{"key":"1218_CR2","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1517\/13543784.15.11.1443","volume":"15","author":"M Zhang","year":"2006","unstructured":"Zhang M, Venable JD, Thurmond RL. The histamine H4 receptor in autoimmune disease. Expert Opin Investig Drugs. 2006;15:1443\u201352.","journal-title":"Expert Opin Investig Drugs"},{"key":"1218_CR3","first-page":"13","volume":"13","author":"DB Frewin","year":"1986","unstructured":"Frewin DB, Cleland LG, Jonsson JR, Robertson PW. Histamine levels in human synovial fluid. J Rheumatol. 1986;13:13\u20134.","journal-title":"J Rheumatol"},{"key":"1218_CR4","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1248\/bpb.28.2016","volume":"28","author":"Y Ikawa","year":"2005","unstructured":"Ikawa Y, Suzuki M, Shiono S, Ohki E, Moriya H, Negishi E, et al. Histamine H4 receptor expression in human synovial cells obtained from patients suffering from rheumatoid arthritis. Biol Pharm Bull. 2005;28:2016\u20138.","journal-title":"Biol Pharm Bull"},{"key":"1218_CR5","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1248\/bpb.30.2217","volume":"30","author":"E Ohki","year":"2007","unstructured":"Ohki E, Suzuki M, Aoe T, Ikawa Y, Negishi E, Ueno K. Expression of histamine H4 receptor in synovial cells from rheumatoid arthritic patients. Biol Pharm Bull. 2007;30:2217\u201320.","journal-title":"Biol Pharm Bull"},{"key":"1218_CR6","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/annrheumdis-2013-203832","volume":"73","author":"JM Cowden","year":"2014","unstructured":"Cowden JM, Yu F, Banie H, Farahani M, Ling P, Nguyen S, et al. The histamine H4 receptor mediates inflammation and Th17 responses in preclinical models of arthritis. Ann Rheum Dis. 2014;73:600\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1218_CR7","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3899\/jrheum.160164","volume":"43","author":"RL Thurmond","year":"2016","unstructured":"Thurmond RL, Greenspan A, Radziszewski W, Xu XL, Miao Y, Chen B, et al. Toreforant, a histamine H4 receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate therapy: results of 2 Phase II studies. J Rheumatol. 2016;43:1637\u201342.","journal-title":"J Rheumatol"},{"key":"1218_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/1529-0131(200001)43:1<164::AID-ANR21>3.0.CO;2-Z","volume":"43","author":"HP Kiener","year":"2000","unstructured":"Kiener HP, Hofbauer R, Tohidast-Akrad M, Walchshofer S, Redlich K, Bitzan P, et al. Tumor necrosis factor alpha promotes the expression of stem cell factor in synovial fibroblasts and their capacity to induce mast cell chemotaxis. Arthritis Rheum. 2000;43:164\u201374.","journal-title":"Arthritis Rheum"},{"key":"1218_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/1529-0131(199802)41:2<233::AID-ART7>3.0.CO;2-V","volume":"41","author":"HP Kiener","year":"1998","unstructured":"Kiener HP, Baghestanian M, Dominkus M, Walchshofer S, Ghannadan M, Willheim M, et al. Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:233\u201345.","journal-title":"Arthritis Rheum"},{"key":"1218_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ajpath.2011.09.028","volume":"180","author":"S Mommert","year":"2012","unstructured":"Mommert S, Gschwandtner M, Koether B, Gutzmer R, Werfel T. Human memory Th17 cells express a functional histamine H4 receptor. Am J Pathol. 2012;180:177\u201385.","journal-title":"Am J Pathol"},{"key":"1218_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/imm.12142","volume":"141","author":"BW Kirkham","year":"2014","unstructured":"Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141:133\u201342.","journal-title":"Immunology"},{"key":"1218_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cyto.2014.10.006","volume":"74","author":"DM Roeleveld","year":"2015","unstructured":"Roeleveld DM, Koenders MI. The role of the Th17 cytokines IL-17 and IL-22 in Rheumatoid Arthritis pathogenesis and developments in cytokine immunotherapy. Cytokine. 2015;74:101\u20137.","journal-title":"Cytokine"},{"key":"1218_CR13","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","volume":"74","author":"DL Boyle","year":"2015","unstructured":"Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015;74:1311\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1218_CR14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/ard.2007.074229","volume":"67","author":"A Kavanaugh","year":"2008","unstructured":"Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firestein GS, Kalunian K, et al. Assessment of rituximab\u2019s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis. 2008;67:402\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1218_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/ard.2007.081950","volume":"67","author":"TC Pouw Kraan van der","year":"2008","unstructured":"van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, et al. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. Ann Rheum Dis. 2008;67:563\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1218_CR16","first-page":"1375","volume":"6","author":"N Li","year":"2013","unstructured":"Li N, Wang JC, Liang TH, Zhu MH, Wang JY, Fu XL, et al. Pathologic finding of increased expression of interleukin-17 in the synovial tissue of rheumatoid arthritis patients. Int J Clin Exp Pathol. 2013;6:1375\u20139.","journal-title":"Int J Clin Exp Pathol"},{"key":"1218_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"1218_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van\u2019t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include 28 joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44\u20138.","journal-title":"Arthritis Rheum"},{"key":"1218_CR19","unstructured":"Van Riel PLCM, van Gestel AM, Scott DL. EULAR handbook of clinical assessments in rheumatoid arthritis. Alphen Aan Den Rijn, The Netherlands: Van Zuiden Communications B.V. 2000; 40."},{"key":"1218_CR20","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"G Wells","year":"2009","unstructured":"Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68:954\u201360.","journal-title":"Ann Rheum Dis"},{"key":"1218_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/annrheumdis-2013-204603","volume":"74","author":"S Kelly","year":"2015","unstructured":"Kelly S, Humby F, Filer A, Ng N, Di Cicco M, Hands RE, et al. Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients. Ann Rheum Dis. 2015;74:611\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1218_CR22","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/art.1780340905","volume":"34","author":"GS Firestein","year":"1991","unstructured":"Firestein GS, Paine MM, Littman BH. Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium. Quantitative analysis and effect of intraarticular corticosteroids. Arthritis Rheum. 1991;34:1094\u2013105.","journal-title":"Arthritis Rheum"},{"key":"1218_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/art.1780370207","volume":"37","author":"GS Firestein","year":"1994","unstructured":"Firestein GS, Paine MM, Boyle DL. Mechanisms of methotrexate action in rheumatoid arthritis. Selective decrease in synovial collagenase gene expression. Arthritis Rheum. 1994;37:193\u2013200.","journal-title":"Arthritis Rheum"},{"key":"1218_CR24","doi-asserted-by":"publisher","first-page":"R352-60","DOI":"10.1186\/ar1004","volume":"5","author":"DL Boyle","year":"2003","unstructured":"Boyle DL, Rosengren S, Bugbee W, Kavanaugh A, Firestein GS. Quantitative biomarker analysis of synovial gene expression by real-time PCR. Arthritis Res Ther. 2003;5:R352-60.","journal-title":"Arthritis Res Ther"},{"key":"1218_CR25","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/CDLI.10.6.1002-1010.2003","volume":"10","author":"S Rosengren","year":"2003","unstructured":"Rosengren S, Firestein GS, Boyle DL. Measurement of inflammatory biomarkers in synovial tissue extracts by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2003;10:1002\u201310.","journal-title":"Clin Diagn Lab Immunol"},{"key":"1218_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jdermsci.2017.05.011","volume":"88","author":"SH Han","year":"2017","unstructured":"Han SH, Hur MS, Kim MJ, Kim BM, Kim KW, Kim HR, et al. Preliminary study of histamine H4 receptor expressed on human CD4 + T cells and its immunomodulatory potency in the IL-17 pathway of psoriasis. J Dermatol Sci. 2017;88:29\u201335.","journal-title":"J Dermatol Sci"},{"key":"1218_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1124\/jpet.113.211714","volume":"349","author":"RL Thurmond","year":"2014","unstructured":"Thurmond RL, Chen B, Dunford PJ, Greenspan AJ, Karlsson L, La D, et al. Clinical and preclinical characterization of the histamine H4 receptor antagonist JNJ-39758979. J Pharmacol Exp Ther. 2014;349:176\u201384.","journal-title":"J Pharmacol Exp Ther"},{"key":"1218_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/rheumatology\/kei209","volume":"45","author":"T Iwamoto","year":"2006","unstructured":"Iwamoto T, Okamoto H, Iikuni N, Takeuchi M, Toyama Y, Tomatsu T, et al. Monocyte chemoattractant protein-4 (MCP-4)\/CCL13 is highly expressed in cartilage from patients with rheumatoid arthritis. Rheumatology. 2006;45:421\u20134.","journal-title":"Rheumatology"},{"key":"1218_CR29","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/rheumatology\/kes381","volume":"52","author":"MK Doyle","year":"2013","unstructured":"Doyle MK, Rahman MU, Frederick B, Birbara CA, de Vries D, Toedter G, et al. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. Rheumatology. 2013;52:1214\u20139.","journal-title":"Rheumatology"},{"key":"1218_CR30","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1136\/annrheumdis-2011-200963","volume":"71","author":"MF Bakker","year":"2012","unstructured":"Bakker MF, Cavet G, Jacobs JW, Bijlsma JW, Haney DJ, Shen Y, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis. 2012;71:1692\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1218_CR31","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1136\/ard.2008.091876","volume":"68","author":"MH Buch","year":"2009","unstructured":"Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis. 2009;68:1220\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1218_CR32","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.4049\/jimmunol.0903566","volume":"184","author":"AJ Hueber","year":"2010","unstructured":"Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol. 2010;184:3336\u201340.","journal-title":"J Immunol"},{"key":"1218_CR33","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E","volume":"42","author":"M Chabaud","year":"1999","unstructured":"Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999;42:963\u201370.","journal-title":"Arthritis Rheum"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00011-019-01218-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-019-01218-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-019-01218-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T05:43:44Z","timestamp":1606455824000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00011-019-01218-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,9]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1218"],"URL":"https:\/\/doi.org\/10.1007\/s00011-019-01218-y","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,9]]},"assertion":[{"value":"15 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SE DePrimo, C Calderon, D Chen, PJ Dunford*, W Barchuk*, and RL Thurmond are\/were employees of Janssen, a Johnson and Johnson (J&J) Pharmaceutical Company, and own stock in J&J. DL Boyle and GS Firestein have each received research grant funding from Janssen. *These authors were employed by Janssen at the time this study was conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with ethical standards of the institutional review board and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained for all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}